Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail sector is experiencing continuous operational pressure, with a focus on high-prosperity quality companies [4][24] - The overall revenue for the retail industry in 2024 and Q1 2025 decreased by 1.8% and 13.3% year-on-year, respectively, while the net profit attributable to the parent company decreased by 20.6% and 21.3% [4][24] - The report highlights the performance of various segments, including jewelry, beauty care, and cross-border e-commerce, with specific recommendations for investment opportunities [7][43] Summary by Relevant Sections Retail Market Overview - The retail industry index fell by 1.72% in the week of April 28 to April 30, 2025, underperforming the Shanghai Composite Index [6][15] - The beauty products segment showed the highest increase, with a weekly rise of 7.49% and a year-to-date increase of 12.66% [15][19] Industry Dynamics - The retail sector's financial reports indicate ongoing operational challenges, with a focus on high-prosperity segments [4][24] - The jewelry segment's revenue decreased by 4.9% in 2024 and 25.9% in Q1 2025, while the beauty care segment saw a revenue increase of 5.3% in 2024 but a slight decline of 1.7% in Q1 2025 [4][33][28] Investment Recommendations - Investment focus areas include traditional retail, jewelry, cosmetics, and medical aesthetics, with specific companies recommended for their growth potential [7][43] - Key recommended companies include Yonghui Supermarket, Aiyingshi, and various beauty brands such as Maogeping and Pulaia [7][46][44] Segment Performance - Cross-border e-commerce showed strong growth with a revenue increase of 31.9% in 2024 and 28.8% in Q1 2025, indicating a robust operational environment [4][38] - The beauty care segment is expected to maintain growth through differentiated products and strong brand positioning [28][44]

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - Retail enterprises are under continuous operational pressure, with a focus on high-prosperity quality companies [4][24] - The overall revenue of the retail industry decreased by 1.8% in 2024 and 13.3% in Q1 2025, while the net profit attributable to the parent company decreased by 20.6% and 21.3% respectively [4][24] - The jewelry sector faced revenue declines of 4.9% in 2024 and 25.9% in Q1 2025, with net profit declines of 17.7% and 18.8% respectively [4][33] - The beauty care sector showed a revenue increase of 5.3% in 2024 but a slight decline of 1.7% in Q1 2025, with net profit declines of 17.5% and 21.7% respectively [4][28] - The cross-border e-commerce sector experienced significant growth, with revenue increases of 31.9% in 2024 and 28.8% in Q1 2025, while net profit showed a decline of 4.6% and an increase of 4.9% respectively [4][38] Summary by Sections Retail Market Overview - The retail industry index decreased by 1.72% in the week of April 28 to April 30, 2025, underperforming the Shanghai Composite Index [6][15] - The beauty products sector had the highest growth, with a weekly increase of 7.49% and a year-to-date increase of 12.66% [15][19] Industry Dynamics - The financial reports for 2024 and Q1 2025 indicate that retail enterprises are facing operational challenges, with a focus on high-prosperity sectors [4][24] - The jewelry sector is under pressure due to rising gold prices affecting consumer demand and operational challenges for weaker franchisees [4][33] - The beauty care sector remains relatively stable, with strong performance from differentiated beauty brands [4][28] Investment Recommendations - Focus on traditional retail companies that adapt to consumer trends, such as Yonghui Supermarket and Aiyingshi [7][43] - Highlight jewelry brands with differentiated product offerings, recommending brands like Laopu Gold and Chaohongji [7][43] - Emphasize domestic beauty brands that are expanding into high-prosperity segments, recommending brands like Maogeping and Shangmei [7][44] - Target upstream medical beauty product manufacturers with strong profitability, recommending companies like Aimeike and Kedi [7][44]

Core Insights - The medical aesthetics industry is facing significant challenges, with "difficult operations" becoming a consensus within the sector. Even large listed companies like Langzi Medical Beauty are struggling with performance growth [1][10] - Langzi Medical Beauty's revenue for 2024 was 5.691 billion yuan, showing a slight decline compared to the previous year, and the first quarter of 2025 continued to show weakness with a revenue of 1.399 billion yuan, down 7.77% year-on-year [1][10] Company Overview - Langzi Co., Ltd. initially focused on mid-to-high-end women's clothing, founded in 2000, and later expanded into children's clothing. However, the company faced significant challenges due to the rise of e-commerce and foreign luxury brands [1][2] - In 2016, Langzi entered the medical aesthetics market through strategic investments and acquisitions, including a notable investment in the Korean medical beauty service group DMG [2][3] Business Expansion - The company adopted an aggressive acquisition strategy, acquiring multiple medical aesthetics brands and institutions from 2016 onwards, including the acquisition of 100% of Shaanxi Gao Yisheng in 2017 and several others in subsequent years [3][4] - By 2024, the medical aesthetics segment contributed 49% of Langzi's revenue and 45% of its gross profit, surpassing its original women's clothing and children's business segments [4][5] Financial Performance - Despite the successful transition to the medical aesthetics sector, the expected high growth has not materialized. The company's net profit for 2024 was 218 million yuan, only slightly above the 204 million yuan net profit in 2013 when it focused on women's clothing [5][6] - The medical aesthetics business had a revenue of approximately 2.784 billion yuan in 2024, with a year-on-year growth of only 3.47%, and the lowest gross margin among the three business lines at 54.42% [5][7] Challenges and Risks - The company faces increasing competition in the medical aesthetics industry, with a general slowdown in growth and economic conditions impacting performance across all business lines [10] - Langzi's goodwill has significantly increased due to its acquisition strategy, with goodwill assets amounting to 1.781 billion yuan, representing 64% of its net assets. This raises concerns about potential impairment risks in the future [8][9] - The company's short-term debt has surged, with 1.323 billion yuan due within a year, while cash reserves stand at only 555 million yuan, indicating weak short-term solvency [9][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve stable performance in 2024, with a focus on both organic growth and external expansion in the medical aesthetics sector [4] - The company reported a slight decline in revenue for 2024, with total revenue of 56.91 billion yuan, a year-on-year decrease of 0.2%, while net profit attributable to the parent company increased by 1.4% to 2.57 billion yuan [4][5] - The forecast for net profit attributable to the parent company for 2025-2027 is adjusted to 2.84 billion yuan, 3.20 billion yuan, and 3.64 billion yuan respectively, with corresponding EPS of 0.64, 0.72, and 0.82 yuan [4] Financial Performance Summary - In 2024, the medical aesthetics segment generated revenue of 27.84 billion yuan, up 3.5%, with a gross margin of 54.4% [5] - The women's clothing segment saw revenue of 19.25 billion yuan, down 3.0%, while the children's clothing segment reported revenue of 9.21 billion yuan, down 5.5% [5] - The overall gross margin for the company improved to 58.8%, with surgical and non-surgical gross margins at 47.1% and 55.6% respectively [5] Business Expansion Strategy - The company is actively expanding its medical aesthetics footprint through acquisitions, having integrated several medical beauty institutions into its financial reports [6] - The company has invested in upstream medical aesthetics equipment research and production, indicating a strategic move towards vertical integration [6] - The women's clothing and children's clothing segments are focusing on enhancing their online sales channels and operational efficiency [6] Financial Projections - Revenue projections for 2025-2027 are set at 61.12 billion yuan, 64.80 billion yuan, and 68.16 billion yuan respectively, with a compound annual growth rate expected [7] - The projected net profit for 2025-2027 is 284 million yuan, 320 million yuan, and 364 million yuan, reflecting a steady growth trajectory [7] - The company's P/E ratio is projected to decrease from 24.8 in 2025 to 19.3 in 2027, indicating an improving valuation [7]

Group 1 - Chengdu's delegation visited South Korea and Japan from April 21 to 28 to deepen economic and trade cooperation, focusing on electronic information, automotive, and medical aesthetics industries [1][2] - A total of 12 cooperation projects were signed between Chengdu and South Korea, with a total investment amount of 3.12 billion yuan [1][2] - Four industrial projects were signed in Chengdu, including HCT's China headquarters and testing laboratory, with a total investment of 1.21 billion yuan, covering electronic information, biomedicine, and new consumption sectors [3] Group 2 - Eight outward-oriented enterprises from Chengdu signed eight business cooperation projects with South Korean companies, amounting to 1.91 billion yuan, involving electronic information, biomedicine, and health sectors [4] - The cooperation aims to promote the production and marketing of new pharmaceuticals and medical devices from South Korea in Chengdu, while accelerating the international market expansion of Chengdu's unique products [4] - The event is seen as a platform for deepening cooperation between Chinese and South Korean enterprises, enhancing their collaboration in the global market [4]

Core Insights - The report provides a comprehensive analysis of the high-end women's clothing industry in China, focusing on market trends, consumer behavior, and competitive landscape leading up to 2025 [1] Group 1: Industry Overview - The high-end women's clothing market is categorized into various segments including dresses, professional attire, fashion wear, and trousers [4] - Key international high-end women's clothing brands are introduced, highlighting their market presence and influence [4] Group 2: Market Environment Analysis - The macroeconomic environment for 2025 indicates a positive GDP growth outlook, which is expected to support the high-end women's clothing market [5] - The report discusses the regulatory framework governing the industry, including relevant laws and policies affecting retail operations [5] Group 3: Market Development Analysis - The high-end women's clothing sector is experiencing a notable trend towards premiumization, with increasing consumer demand for high-quality products [6] - The market size for high-end women's clothing is projected to grow, driven by rising disposable incomes and a growing middle class [6] Group 4: Competitive Landscape - The competitive landscape shows a low concentration of brands, with many domestic players competing against established international brands [7] - The report highlights the competitive advantages of foreign brands, such as brand recognition and established distribution channels [7] Group 5: Marketing Strategies - High-end women's clothing brands are adopting multi-channel marketing strategies to enhance their market reach and consumer engagement [8] - The report emphasizes the importance of visual merchandising and brand storytelling in attracting consumers [8] Group 6: Future Outlook - The high-end women's clothing market is expected to see significant growth from 2025 to 2031, with opportunities for domestic brands to capture market share [10] - The report suggests that investment in brand culture and operational capabilities will be crucial for success in the evolving market landscape [10]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][12] Core Views - The company's Q1 2025 revenue reached 1.399 billion, a year-on-year decrease of 7.77%, while the net profit attributable to the parent company was 95 million, an increase of 5.12% year-on-year. The medical beauty business is steadily advancing, with a revenue contribution of 48.92% from this segment by the end of 2024 [1][3][6] - The medical beauty industry has significant growth potential due to increasing consumer penetration and the enhancement of quality product supply. The company is actively pursuing mergers and acquisitions to expand its national medical beauty ecosystem, which will enhance its overall scale and brand influence [3][12][4] Financial Performance - In Q1 2025, the company achieved a gross margin of 59.72%, an increase of 0.17 percentage points year-on-year, benefiting from cost control and improved brand strength. The sales expense ratio was 39.63%, down 0.42 percentage points year-on-year, while the management expense ratio remained stable at 8.14% [2][10] - The company forecasts a net profit of 292 million for 2025, down from a previous estimate of 381 million, with projected profits of 327 million in 2026 and 370 million in 2027, corresponding to P/E ratios of 34.1, 30.5, and 26.9 respectively [3][4][12] Revenue and Profit Forecast - The company expects to generate revenues of 6.327 billion in 2025, with a growth rate of 11.18%, and a net profit of 292 million, reflecting a growth rate of 13.56% [4][14] - The projected revenue for 2026 is 7.059 billion, with a net profit of 327 million, and for 2027, the revenue is expected to reach 7.827 billion with a net profit of 370 million [4][14]

Core Viewpoint - The company has released its first quarter report for 2025, ensuring the accuracy and completeness of the information disclosed, with no false records or misleading statements [1][2][7]. Financial Data - The first quarter report has not been audited [3][6]. - The company has made retrospective adjustments to previous accounting data due to a business combination under common control [3][4]. - There are no non-recurring profit and loss items applicable for the quarter [3]. Governance and Compliance - The board of directors and supervisory board have confirmed the authenticity and completeness of the quarterly report, taking legal responsibility for its content [2][12]. - The meetings of both the board and supervisory board were conducted in compliance with relevant laws and regulations, ensuring their legality and validity [7][11]. Shareholder Information - The report includes details on the total number of ordinary shareholders and the shareholding status of the top ten shareholders, although specific data is not provided in the excerpts [5].

Financial Performance - The basic earnings per share for Q1 2025 is 0.2153 yuan, representing a 5.13% increase compared to Q1 2024's 0.2048 yuan and a significant increase from Q1 2023's 0.1603 yuan [1] - The net profit for Q1 2025 is 0.95 billion yuan, which is a 4.4% increase from Q1 2024's 0.91 billion yuan and an increase from Q1 2023's 0.71 billion yuan [1] - The operating revenue for Q1 2025 is 13.99 billion yuan, showing a decrease of 7.78% from Q1 2024's 15.17 billion yuan, but an increase from Q1 2023's 12.56 billion yuan [1] - The return on equity for Q1 2025 is 3.36%, which is a 23.53% increase compared to Q1 2024's 2.72% and an increase from Q1 2023's 2.14% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 82.482 million shares, accounting for 32.39% of the circulating shares, with a decrease of 1.0847 million shares compared to the previous period [1] - The largest shareholder, Shen Dongri, holds 52.8898 million shares, representing 20.76% of the total share capital, with no change in holdings [2] - New entrant in the top ten shareholders is Zhang Quanmei, holding 1.3988 million shares, representing 0.55% of the total share capital [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [3]

证券代码：002612 证券简称：朗姿股份 公告编号：2025-030 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届监事会第十四次 会议通知于 2025 年 4 月 23 日以专人送达、电子邮件等方式发出，并于 2025 年 4 月 25 日以通讯及现场会议方式召开。会议由监事会主席李婷女士主持，会议 应出席监事 3 名，实际出席监事 3 名，公司董事会秘书王建优先生列席本次会 议。会议的召集和召开符合《中华人民共和国公司法》《朗姿股份有限公司章程》 和《朗姿股份有限公司监事会议事规则》等有关规定，会议合法有效。 二、监事会会议审议情况 朗姿股份有限公司 第五届监事会第十四次会议决议公告 1、审议并通过了《2025 年第一季度报告》 监事会认为：公司《2025 年第一季度报告》符合法律、行政法规、中国证监 会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 《 2025 年第一季度报告 》详见公司同日刊登在巨潮资讯网 （www ...